Cargando…

Effect of axitinib regulating the pathological blood–brain barrier functional recovery for glioblastoma therapeutics

AIMS: Dysfunction of the blood–brain barrier (BBB) is a prominent pathological feature of glioblastoma (GBM). Vascular endothelial growth factor (VEGF) is confirmed to be abnormally elevated in the pathogenesis of GBM, causing BBB pathological disruption, which further allows the leakage of neurotox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fengtian, Wen, Lijuan, Wang, Kai, Huang, Zhihua, Jin, Xiangyu, Xiong, Ruiwen, He, Shiying, Hu, Fuqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841308/ https://www.ncbi.nlm.nih.gov/pubmed/34967104 http://dx.doi.org/10.1111/cns.13788

Ejemplares similares

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics
por: WANG, KAI, et al.
Publicado: (2022)

Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment
por: Cai, Qi, et al.
Publicado: (2023)

In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology
por: Opriţa, Alexandru, et al.
Publicado: (2023)

Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
por: Tang, Lin, et al.
Publicado: (2021)

Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model
por: Sulheim, Einar, et al.
Publicado: (2019)

Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model
por: Merolle, Matilde, et al.
Publicado: (2020)

Neurosurgical Techniques for Disruption of the Blood–Brain Barrier for Glioblastoma Treatment
por: Rodriguez, Analiz, et al.
Publicado: (2015)

Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
por: Da Ros, Martina, et al.
Publicado: (2018)

Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme
por: Jena, Lynn, et al.
Publicado: (2019)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Encapsulated n-Butylidenephthalide Efficiently Crosses the Blood–Brain Barrier and Suppresses Growth of Glioblastoma
por: Lin, Yu-Ling, et al.
Publicado: (2020)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

The Blood−Brain Barrier in Neuroimmune Interactions and Pathological Processes
por: Dyatlova, A. S., et al.
Publicado: (2022)

Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells
por: Krcek, Reinhardt, et al.
Publicado: (2017)

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2020)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Cnf1 Variants Endowed with the Ability to Cross the Blood–Brain Barrier: A New Potential Therapeutic Strategy for Glioblastoma
por: Colarusso, Andrea, et al.
Publicado: (2020)

Focused ultrasound-mediated blood-brain barrier opening combined with magnetic targeting cytomembrane based biomimetic microbubbles for glioblastoma therapy
por: He, Chuanshi, et al.
Publicado: (2023)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
por: Wei, Na, et al.
Publicado: (2018)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
por: Zhang, Bo-Wen, et al.
Publicado: (2022)

Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma
por: Harder, Bryan G., et al.
Publicado: (2018)

A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma
por: Ozawa, Tomoko, et al.
Publicado: (2021)

Exosomes: Promising Delivery Tools for Overcoming Blood-Brain Barrier and Glioblastoma Therapy
por: Khatami, Seyyed Hossein, et al.
Publicado: (2023)

Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
por: Pardridge, William M.
Publicado: (2020)

The influence of physiological and pathological perturbations on blood-brain barrier function
por: Zhao, Nan, et al.
Publicado: (2023)

Physiological and pathological consequences of exosomes at the blood–brain-barrier interface
por: Salimi, Leila, et al.
Publicado: (2023)

Blood–brain barrier: a real obstacle for therapeutics
por: Shiekh, Farooq A
Publicado: (2012)

Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy
por: Kim, Dong Geon, et al.
Publicado: (2016)

One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma
por: Park, So Hee, et al.
Publicado: (2020)

Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier
por: Sharma, Rohit K., et al.
Publicado: (2021)

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
por: Li, Jia, et al.
Publicado: (2021)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
por: Hillman, Gilda G., et al.
Publicado: (2014)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
por: Kerr, Lauren T., et al.
Publicado: (2016)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_62pcoal63pv1gj5cvg3qa1runq